Thomas Andrew Burrow

Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease

Manoj K. Pandey, Thomas Andrew Burrow, Reena Rani et al. · Nature · 2017 · 185 citations

Inflammation, Chronic Inflammatory Diseases, Complement System +11

Clinical Impact and Cost-Effectiveness of Whole Exome Sequencing as a Diagnostic Tool: A Pediatric Center’s Experience

C. Alexander Valencia, Ammar Husami, Jennifer Holle et al. · Frontiers in Pediatrics · 2015 · 179 citations · Full text

Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial

Timothy M. Cox, Guillermo Drelichman, Renata Cravo et al. · The Lancet · 2015 · 150 citations

Enzyme Replacement Therapy, Substrate Reduction Therapy, Disease Type 1 +2

Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial

Benedikt Schoser, Mark Roberts, Barry J. Byrne et al. · The Lancet Neurology · 2021 · 124 citations

Clinical Trials, Cipaglucosidase Alfa, Pharmacotherapy +2

De novo mutations in KIF1A cause progressive encephalopathy and brain atrophy

Sahar Esmaeeli Nieh, Maura R.Z. Madou, Minhajuddin Sirajuddin et al. · Annals of Clinical and Translational Neurology · 2015 · 119 citations · Full text